Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.

Drug Design, Development and Therapy
Massimo OffidaniAttilio Olivieri

Abstract

Despite the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and, more recently, monoclonal antibodies (mAbs), in the chemotherapy regimens for newly diagnosed (NDMM) and relapsed/refractory MM (RRMM), the occurrence of drug resistance remains a challenge in MM patients. This is mainly in the advanced stage of the disease when treatments are limited, and the prognosis is abysmal. Nevertheless, novel molecules and therapeutic approaches are rapidly moving through the several phases of drug development and could address the need for new treatment options. The recent innovative B-cell maturation antigen (BCMA) targeted immunotherapies, such as belantamab mafodotin, the first-in-class monoclonal antibody-drug conjugate (ADC), induce an effective and durable response in triple-class refractory disease and to be approved in MM. In contrast with the other BCMA-targeted therapies as CAR T cells with a complex manufacturing process, and bispecific antibodies, both requiring inpatient hospitalization to monitor the occurrence of severe adverse events, belantamab mafodotin is an "off-the-shelf" drug that can be administered in an outpatient setting. Many belantamab mafodotin-based combinations are under evaluat...Continue Reading

References

Jul 13, 2004·Mayo Clinic Proceedings·Shaji K KumarPhilip R Greipp
Nov 3, 2011·Bone Marrow Research·Yu-Tzu Tai, Kenneth C Anderson
Jul 19, 2012·British Journal of Haematology·Eric SanchezJames R Berenson
Apr 16, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dharminder ChauhanKenneth C Anderson
Dec 6, 2014·Journal of Hematology & Oncology·Giovanni Luca GravinaClaudio Festuccia
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Aug 27, 2015·The New England Journal of Medicine·Henk M LokhorstPaul G Richardson
Nov 6, 2015·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Joshua Seth EatonChristopher J Murphy
Apr 19, 2016·International Journal of Molecular Sciences·Jun LuGe Zhang
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators
Oct 16, 2016·Protein & Cell·Kyoji Tsuchikama, Zhiqiang An
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenneth C Anderson
Mar 3, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaoyan FengKenneth C Anderson
Sep 21, 2017·Blood·Lekha Mikkilineni, James N Kochenderfer
Dec 12, 2017·The New England Journal of Medicine·Joseph M ConnorsUNKNOWN ECHELON-1 Study Group
Dec 13, 2017·The New England Journal of Medicine·María-Victoria MateosUNKNOWN ALCYONE Trial Investigators
Jan 26, 2018·International Journal of Hematology·Hideto Tamura
May 29, 2018·Clinical Lymphoma, Myeloma & Leukemia·Alex F Herrera, Arturo Molina
Nov 8, 2018·The New England Journal of Medicine·Meletios A DimopoulosJesús San-Miguel
Apr 6, 2019·Cancer·Ajay K NookaSagar Lonial
May 30, 2019·The New England Journal of Medicine·Thierry FaconUNKNOWN MAIA Trial Investigators
Aug 23, 2019·The New England Journal of Medicine·Ajai ChariSundar Jagannath
Sep 11, 2019·Journal of Hematology & Oncology·Bo Yu, Delong Liu

❮ Previous
Next ❯

Software Mentioned

Pd
CASTOR
POLLUX
ALGONQUIN
Belamaf
HORIZON
BOSTON

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.